Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries

SHANGHAI and MOSCOW, Dec. 20, 2022 /PRNewswire/ -- Mabwell Bioscience (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, today announced the company has entered into an licensing agreement with the Russian pharmaceutical company Binnopharm Group, for 9M...

2022-12-20 17:00 1961

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapie...

2022-12-19 23:07 1872

SeekIn Receives CE-IVD Mark Approval for PanCanSeek® Cancer Mutation Detection Kit

First-of-its-kind one-for-all cancer mutation detection test SHENZHEN, China, Dec. 19, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for PanCanSeek® Cancer Mutation Detection Kit...

2022-12-19 21:00 1430

Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON

WUHAN, China and SAN DIEGO, Dec. 19, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth")today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on the in-vivo gene replacement therapy NFS-02 (rAAV2-ND1), for the...

2022-12-19 21:00 1601

GenFleet Therapeutics and Merck Enter into Trial Collaboration to Initiate Study Investigating Combination Therapy of GFH925 (KRAS G12C inhibitor) and ERBITUX® (cetuximab)

SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck to start a clinical study of...

2022-12-19 19:00 1360

Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives

--The issue date of the patent will be January 3, 2023 by the United States Patent and Trademark Office (USPTO). The patent number is 11,541,071 -- The issued patent covers ASC10 and its derivatives, and their uses to treat virus infections including SARS-CoV-2, monkeypox virus and respiratory s...

2022-12-19 18:10 1847

Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines

TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received the clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC610, fr...

2022-12-19 13:53 2105

TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody

HEFEI, China, Dec. 17, 2022 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (Hefei, China), an innovative biotech company dedicated to the discovery of novel immunotherapeutic drugs and a leader in NK cell research globally, today announced that the U.S. Food and Drug Administration (FDA) has cleared i...

2022-12-17 21:30 2704

Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology

* Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform * Cancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Gra...

2022-12-16 19:56 3069

Novavax Announces Pricing of $65 Million Public Offering of Common Stock

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of ...

2022-12-16 14:49 4548

Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of$150 million aggregate principal amount of its ...

2022-12-16 14:18 3575

Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer

HANGZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Hangzhou, Zhejiang, China, [ December 9th, 2022], Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered ...

2022-12-16 09:00 1569

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Depar...

2022-12-16 08:44 1869

Bioved Pharmaceuticals, Inc. announces the results of its Phase III Randomized Clinical Trial in Moderate Covid-19 with Artovid-20®, a natural plant-based oral product

SAN JOSE, Calif., Dec. 16, 2022 /PRNewswire/ -- Published Nov 25, 2022 in the highly respected peer-reviewed journal Phytotherapy Research, results show statistically significant reduction in duration of illness and severity scores of the symptoms associated with Covid-19. In addition, statistica...

2022-12-16 01:30 1929

China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19

HAIKOU, China, Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that its drugs were listed in The...

2022-12-15 21:00 1470

Nevisense for skin barrier evaluation included in large Australian birth cohort study

STOCKHOLM, Dec. 15, 2022 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that SciBase has received an order for skin barrier assessment products to be included in one of the world's large...

2022-12-15 15:50 1483

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Ph...

2022-12-15 14:00 2344

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

GUANGZHOU, China , Dec. 15, 2022 /PRNewswire/ -- On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as "Biosyngen") made an announcement on the approval granted by the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) for the company's IND appl...

2022-12-15 13:08 3666

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

"Gowajee" - a Thai Speech-Recognition AI from Chula

BANGKOK, Dec. 15, 2022 /PRNewswire/ -- Chula Engineering professors have designed "Gowajee", a Thai-language speech recognition AI with the accuracy of a native speaker that keeps users' data secure – now rolled out in call centers, and being used for depression patients screening.

2022-12-15 09:00 2722

Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease

ROCKVILLE, Md. and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Innovent Biologics ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other m...

2022-12-15 08:00 3086

1 ... 91 92 939495 96 97 ... 293